Development and evaluation of an HIV-1 transfection-neutralization assay

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Evaluating the neutralizing capacity of antibodies against human immunodeficiency virus type 1 (HIV-1) is crucial for vaccine development and therapeutic strategies.
• Conventional cell-free infection inhibition assays require extensive virus stock preparation, which can be challenging for certain HIV-1 molecular clones.

Purpose of the Study:

• To develop and validate a novel transfection-neutralization assay for assessing neutralizing antibodies against HIV-1 infectious molecular clones.
• To provide a more efficient and versatile method for evaluating HIV-1 clones, particularly those with slow replication or prone to mutations during stock preparation.

Main Methods:

• Development of a transfection-neutralization assay using CD4-negative cells transfected with proviral DNA.
• Co-cultivation of transfected cells with CD4-positive T cell lines or peripheral blood mononuclear cells (PBMC) in the presence of anti-HIV-1 sera or monoclonal antibodies (MAbs).
• Comparison of results with a conventional cell-free infection inhibition assay.

Main Results:

• The transfection-neutralization assay demonstrated reproducible results.
• The assay performance compared favorably with the conventional cell-free infection inhibition assay.
• The assay proved valuable for analyzing the specificity of neutralizing sera and MAbs, particularly with V3 chimeric molecular clones.

Conclusions:

• The developed transfection-neutralization assay is a reliable and efficient method for evaluating neutralizing antibodies against HIV-1 molecular clones.
• This assay obviates the need for virus stock preparation, making it suitable for challenging HIV-1 clones and recombinant constructs.
• The assay has significant potential for analyzing the specificity of neutralizing antibodies and characterizing HIV-1 diversity.